Client Reference: 1999-30-0466A

DEC 3 1 2003 2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

n Re The Application of HANNA et al.

Group Art Unit: 1644

Application No.: 09/435,992

Examiner: Phillip Gambel

Filed: November 8, 1999

Confirmation No.: 5990

For: TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN

COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND

RADIOTHERAPY

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance. Payment of the requisite fee under 37 CFR 1.17(p) is enclosed.

Respectfully Submitted,

01/08/2004 AWONDAF1 00000037 033975 09435992

02 FC:1806

180.00 DA

Thomas A. Cawley, Jr., Ph.D. Registration Number 40.944

Customer Number: 00909

Date: December 31, 2003

PILLSBURY WINTHROP LLP Telephone: (703) 905-2000 Facsimile: (703) 905-2500

P.O. Box 10500 McLean, VA 22102

TAC/JBM:ntb

FORM PTO-1449 (modified) To: U.S: Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office								Atty. Dkt. No.				Client Ref.			
/01, 5%								0275478		1999-30-0466A					
BY APPLICANT								Applicant: HANNA et al.							
								Appln. No.: 09/435,992							
TRADEMAN TRADEMAN								Filing Date: November 8, 1999							
Date: D	December 3 ¹	1, 2003	Page	1	of	1		Examiner	: Phillip Gamb	el Gro	up Art Unit	: 1	644		
U.S. PA	TENT DOC	UMENTS													
Examiner's Initials*		Document Number		Date MM/		Nam (Fam		of First Inv	ventor)	Class	Sub Class		Filing Date		
	AR	6,183,744 B1		02/2001		GOLDENBER									
	BR	6,306,393 B1		10/20	001	GOL	DENBER	G		ļ					
	CR			<u> </u>		<u> </u>	<u> </u>								
	DR			-		 									
	ER_			1		-					<u> </u>		<u> </u>		
	FR	5 5 6 6 11 4 5 1 7		<u> </u>				-		<u> </u>			<u> </u>		
FOREIG	SN PATENT	DOCUMENTS Document Date Number MM/Y		Count		itry	Inventor Name				English Abstract			Translation Readily Available	
	GR	0892643 B1	06/20	02	EP		LARSEN	l et al.							
	HR														
	IR														
	JR												ļ		
	KR							Market and the second				_	<u> </u>	\bot	
	LR													<u> </u>	
OTHER		<u></u>													
	MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, Antibody Immunoconjugates, and Radiopharmaceuticals, Vol. 3, No. 1, Abstract No. 83.													
	NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, p. 271, Abstract No. 1051.													
	OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.													
	PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.													
	QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.													
	RR	Kaminski, et a	al., "Im	aging	, Dosir	netry,	and Rad	ioimmunot	herapy With loo						
	SR	Jensen, et al., "Rapid tumor lysis in a patient with B-cell chronic lymphocytic leukemia and lymphocytosis treated with an anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab)," 1998, <i>Ann Hematol</i> , 77:89-91.													
	TR	†													
Examine	er			_				Date Con	sidered:						
*EXAM		ial if citation con							e with MPEP § 6 n to Applicant.	09. Draw	v line throug	gh c	itation if	not	